ドライアイ疾患のグローバル市場2023〜2032

【英語タイトル】GLOBAL DRY EYE DISEASE MARKET FORECAST 2023-2032

Inkwood Researchが出版した調査資料(INK23JUL006)・商品コード:INK23JUL006
・発行会社(調査会社):Inkwood Research
・発行日:2023年5月8日
・ページ数:237
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算¥684,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Inkwood Research社の本調査レポートによると、ドライアイ疾患の世界市場が2023年〜2032年にかけて年平均5.11%で拡大すると見込まれています。本書は、ドライアイ疾患の世界市場について調査し、市場状況や今後の展望を整理しています。調査範囲・調査手法、エグゼクティブサマリー、市場動向、主要分析、種類別(OTC医薬品、処方薬)分析、製品別(抗炎症薬、人工涙液 、涙点プラグ、分泌促進薬、その他)分析、流通チャネル別(病院薬局、独立薬局・ドラッグストア、オンライン薬局)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ、アメリカ、カナダ、イギリス、ドイツ、フランス、イタリア、スペイン、中国、日本、インド、韓国、インドネシア、その他地域)分析、競争状況などの項目が掲載されています。また、市場参入企業として、AFT PHARMACEUTICALS、ALCON、ALLERGAN PLC (ACQUIRED BY ABBVIE)、BAUSCH HEALTH COMPANIES INC、JOHNSON & JOHNSON、NOVALIQ GMBHなどの情報が含まれています。
・調査範囲・調査手法
・エグゼクティブサマリー
・市場動向
・主要分析
・世界のドライアイ疾患市場規模:種類別
- OTC医薬品の市場規模
- 処方薬の市場規模
・世界のドライアイ疾患市場規模:製品別
- 抗炎症薬の市場規模
- 人工涙液の市場規模
- 涙点プラグの市場規模
- 分泌促進薬の市場規模
- その他製品の市場規模
・世界のドライアイ疾患市場規模:流通チャネル別
- 病院薬局チャネルの市場規模
- 独立薬局・ドラッグストアチャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界のドライアイ疾患市場規模:地域別
- 北米のドライアイ疾患市場規模
- ヨーロッパのドライアイ疾患市場規模
- アジア太平洋のドライアイ疾患市場規模
- 中南米のドライアイ疾患市場規模
- 中東/アフリカのドライアイ疾患市場規模
- アメリカのドライアイ疾患市場規模
- カナダのドライアイ疾患市場規模
- イギリスのドライアイ疾患市場規模
- ドイツのドライアイ疾患市場規模
- フランスのドライアイ疾患市場規模
- イタリアのドライアイ疾患市場規模
- スペインのドライアイ疾患市場規模
- 中国のドライアイ疾患市場規模
- 日本のドライアイ疾患市場規模
- インドのドライアイ疾患市場規模
- 韓国のドライアイ疾患市場規模
- インドネシアのドライアイ疾患市場規模
- その他地域のドライアイ疾患市場規模
・競争状況

KEY FINDINGS
The global dry eye disease market is forecasted to record a CAGR of 5.11% during the projected period of 2023-2032. The market growth is ascribed to factors such as the launch of promising pipeline products for dry eye disease, the introduction of new diagnostic techniques for dry eye disease, and the increasing incidence of dry eye among different age groups.

MARKET INSIGHTS
Dry eye is a chronic syndrome, progressive depending on the severity and cause. It is a condition when a person does not have tears to lubricate their eyes. Tears are a vital part of maintaining good eye health and assist in ensuring good vision. The syndrome is typically witnessed among older people. However, it is also becoming common among people who spend long hours in front of the computer.
The accurate diagnosis of dry eye disease is pivotal. Whether it is a practice focusing on a subspecialty, such as glaucoma and retina, or a primary anterior segment practice, the symptoms and signs of dry eye disease are widespread across modern lifestyles. Technological advancements are being made in the field of ophthalmology. Leading firms operating in the market continually concentrate on developing novel therapeutics and diagnostics, as well. For instance, TearScience, a subsidiary of Johnson & Johnson, introduced the latest diagnostic system for dry eye disease in the market, named LipiView II Ocular Surface Interferometer.

REGIONAL INSIGHTS
The global dry eye disease market growth evaluation entails the assessment of the Asia-Pacific, Europe, North America, and the Rest of World. The Asia-Pacific is set to grow with the highest CAGR over the forecasting years due to the increasing number of ophthalmologists in countries like China, India, and Japan, providing good treatment and diagnostic services for ophthalmic conditions and the growing ophthalmic education.

COMPETITIVE INSIGHTS
Significant competition exists between key market players for the development of a new treatment for dry eye disease. The highly sustainable competitive advantages through innovation are likely to intensify rivalry among firms. Besides, solid strategies are anticipated to raise the competition in the market studied.
Some of the top companies operating in the market are Johnson & Johnson, Allergan PLC (Acquired by Abbvie), Bausch Health Companies Inc, etc.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
2.5.2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
2.5.3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
2.5.4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
3.1.3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS
3.2.2. SUBSTITUTE THERAPIES
3.2.3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. MANUFACTURING
4.7.3. DISTRIBUTORS
4.7.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DISTRIBUTION CHANNEL
7.1. HOSPITAL PHARMACIES
7.2. INDEPENDENT PHARMACIES AND DRUGSTORES
7.3. ONLINE PHARMACIES
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. NORTH AMERICA DRY EYE DISEASE MARKET DRIVERS
8.1.3. NORTH AMERICA DRY EYE DISEASE MARKET CHALLENGES
8.1.4. NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.1.5. KEY PLAYERS IN NORTH AMERICA DRY EYE DISEASE MARKET
8.1.6. COUNTRY ANALYSIS
8.1.6.1. UNITED STATES
8.1.6.1.1. UNITED STATES DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.2. CANADA
8.1.6.2.1. CANADA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2. EUROPE
8.2.1. MARKET SIZE & ESTIMATES
8.2.2. EUROPE DRY EYE DISEASE MARKET DRIVERS
8.2.3. EUROPE DRY EYE DISEASE MARKET CHALLENGES
8.2.4. EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.2.5. KEY PLAYERS IN EUROPE DRY EYE DISEASE MARKET
8.2.6. COUNTRY ANALYSIS
8.2.6.1. UNITED KINGDOM
8.2.6.1.1. UNITED KINGDOM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.2. GERMANY
8.2.6.2.1. GERMANY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.3. FRANCE
8.2.6.3.1. FRANCE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.4. ITALY
8.2.6.4.1. ITALY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.5. BELGIUM
8.2.6.5.1. BELGIUM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.6. SPAIN
8.2.6.6.1. SPAIN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.7. POLAND
8.2.6.7.1. POLAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.8. REST OF EUROPE
8.2.6.8.1. REST OF EUROPE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3. ASIA-PACIFIC
8.3.1. MARKET SIZE & ESTIMATES
8.3.2. ASIA-PACIFIC DRY EYE DISEASE MARKET DRIVERS
8.3.3. ASIA-PACIFIC DRY EYE DISEASE MARKET CHALLENGES
8.3.4. ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.3.5. KEY PLAYERS IN ASIA-PACIFIC DRY EYE DISEASE MARKET
8.3.6. COUNTRY ANALYSIS
8.3.6.1. CHINA
8.3.6.1.1. CHINA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.2. JAPAN
8.3.6.2.1. JAPAN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.3. INDIA
8.3.6.3.1. INDIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.4. SOUTH KOREA
8.3.6.4.1. SOUTH KOREA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.5. INDONESIA
8.3.6.5.1. INDONESIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.6. THAILAND
8.3.6.6.1. THAILAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.7. AUSTRALIA & NEW ZEALAND
8.3.6.7.1. AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.8. REST OF ASIA-PACIFIC
8.3.6.8.1. REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.4. REST OF WORLD
8.4.1. MARKET SIZE & ESTIMATES
8.4.2. REST OF WORLD DRY EYE DISEASE MARKET DRIVERS
8.4.3. REST OF WORLD DRY EYE DISEASE MARKET CHALLENGES
8.4.4. REST OF WORLD DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.4.5. KEY PLAYERS IN REST OF WORLD DRY EYE DISEASE MARKET
8.4.6. REGIONAL ANALYSIS
8.4.6.1. LATIN AMERICA
8.4.6.1.1. LATIN AMERICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.4.6.2. MIDDLE EAST AND AFRICA
8.4.6.2.1. MIDDLE EAST AND AFRICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. AFT PHARMACEUTICALS
9.2.2. ALCON
9.2.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
9.2.4. BAUSCH HEALTH COMPANIES INC
9.2.5. JOHNSON & JOHNSON
9.2.6. LUMENIS
9.2.7. NOVALIQ GMBH
9.2.8. NOVARTIS AG
9.2.9. OASIS MEDICAL
9.2.10. OTSUKA PHARMACEUTICAL CO LTD
9.2.11. SANTEN PHARMACEUTICAL CO LTD
9.2.12. SENTISS PHARMA PRIVATE LIMITED
9.2.13. SUN PHARMACEUTICAL INDUSTRIES LTD
9.2.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
9.2.15. VISUFARMA

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – DRY EYE DISEASE
TABLE 2: GLOBAL DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: GLOBAL DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 4: GLOBAL OTC MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: GLOBAL OTC MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 6: GLOBAL PRESCRIPTION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: GLOBAL PRESCRIPTION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 8: GLOBAL DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: GLOBAL DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 10: GLOBAL DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 11: GLOBAL DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 12: GLOBAL CYCLOSPORINE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 13: GLOBAL CYCLOSPORINE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 14: GLOBAL CORTICOSTEROID MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 15: GLOBAL CORTICOSTEROID MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 16: GLOBAL OTHER ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 17: GLOBAL OTHER ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 18: GLOBAL ARTIFICIAL TEARS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 19: GLOBAL ARTIFICIAL TEARS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 20: GLOBAL PUNCTAL PLUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 21: GLOBAL PUNCTAL PLUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 22: GLOBAL SECRETAGOGUES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 23: GLOBAL SECRETAGOGUES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 24: GLOBAL OTHER PRODUCTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 25: GLOBAL OTHER PRODUCTS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 26: GLOBAL DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 27: GLOBAL DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 28: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 29: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 30: GLOBAL INDEPENDENT PHARMACIES AND DRUGSTORES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 31: GLOBAL INDEPENDENT PHARMACIES AND DRUGSTORES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 32: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 33: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 34: GLOBAL DRY EYE DISEASE MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 35: GLOBAL DRY EYE DISEASE MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 36: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 37: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 38: NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 39: KEY PLAYERS OPERATING IN NORTH AMERICA DRY EYE DISEASE MARKET
TABLE 40: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 41: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 42: EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 43: KEY PLAYERS OPERATING IN EUROPE DRY EYE DISEASE MARKET
TABLE 44: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 45: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 46: ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 47: KEY PLAYERS OPERATING IN ASIA-PACIFIC DRY EYE DISEASE MARKET
TABLE 48: REST OF WORLD DRY EYE DISEASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 49: REST OF WORLD DRY EYE DISEASE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 50: REST OF WORLD DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 51: KEY PLAYERS OPERATING IN REST OF WORLD DRY EYE DISEASE MARKET
TABLE 52: LIST OF MERGERS & ACQUISITIONS
TABLE 53: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 54: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 55: LIST OF BUSINESS EXPANSIONS & DIVESTITURES


★調査レポート[ドライアイ疾患のグローバル市場2023〜2032] (コード:INK23JUL006)販売に関する免責事項を必ずご確認ください。
★調査レポート[ドライアイ疾患のグローバル市場2023〜2032]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆